India Pharma, Pfizer Continue Words War Over IP Protections
This article was originally published in PharmAsia News
Executive Summary
The Indian Pharmaceutical Alliance and Pfizer are engaging in a war of words over compulsory licensing and protections of U.S. intellectual property in general.